FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
Georg M Haag, Kirsten Merx, Ralf-Dieter Hofheinz, Christoph Springfeld, Wolf Bechstein, Salah-Eddin Al-Batran, Thorsten O Göetze, Claudia Pauligk, Disorn Sookthai, Maria Loose, Fuat S Oduncu, Achim Battmann, Timo Gaiser, Hagen Flach, Peter Reichardt, Daniel Pink, Nils Homann, Rolf Mahlberg, Eray Goekkurt, Matthias P Ebert, Gabriele Siegler, Christian Teschendorf, Albrecht Kretzschmar, Kersten Borchert, Thomas Ettrich
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022;40(32):3750-3761